Recently Featured

Genewiz Launches Gene Synthesis 2.0

May 16, 2026
Genewiz, a genomics services provider under Azenta Life Sciences, has launched Gene Synthesis 2.0, an updated platform aimed at enhancing the efficiency of gene design and ordering for researchers. This new platform features three distinct packages—Sprint, Flex, and Flex—designed to provide a streamlined and intuitive ordering experience. Trey Martin, president of Genewiz, emphasizes that researchers…

Rezdiffra Exceeds Wall Street Expectations as MASH Market Evolves

May 15, 2026
Rezdiffra, a novel therapeutic agent, is outperforming Wall Street projections as the market for metabolic-associated steatotic hepatitis (MASH) begins to solidify. The drug’s promising performance comes in the wake of increasing competition, particularly from Novo Nordisk’s Wegovy, which gained approval in August 2025 for treating fatty liver disease. This evolving landscape indicates a burgeoning interest…

Medicare’s Alzheimer’s Drug Spending Projections Fall Short

May 15, 2026
Medicare’s spending on the Alzheimer’s drug Leqembi is projected to be significantly lower than earlier estimates, with costs expected to be much less than the $3.5 billion forecasted for 2025. This unexpected outcome raises questions about the accuracy of predictive models used by Medicare actuaries and their implications for future drug pricing strategies. The context…

Cellular Intelligence licenses Novo’s shelved Parkinson’s cell therapy programme

May 15, 2026
Cellular Intelligence has secured a licensing agreement for Novo Nordisk’s previously shelved Parkinson’s disease cell therapy programme, a significant pivot in the evolving landscape of neurodegenerative treatments. This development follows Novo Nordisk’s decision to shutter its cell therapy unit in October 2025, marking a strategic retreat from a sector that has seen both promise and…

Ongoing Cases